Please login to the form below
Alimta
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Alimta was produced by Lilly.
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
Lilly’s presence in cancer is led by lung cancer chemotherapy drug Alimta (pemetrexed), which brought in $2.1bn in sales last year down from a peak of around $2.8bn
Lilly scores FDA okay for Cyramza in liver cancer
Last year sales rose 8% to around $820m making it Lilly’s second-largest cancer drug after $2bn lung cancer blockbuster Alimta (pemetrexed), but it has come under pressure as a
Trulicity’s ascent lifts Lilly
The company also recently gained FDA approval for Alimta in combination with Keytruda and platinum chemotherapy for the first-line treatment of patients with metastatic NSCLC with no EGFR or ALK
EMA says Lilly’s Lartruvo should not be prescribed
The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets,
Lilly adds to pharma M&A run with $8bn Loxo buy-out
Lilly does have presence in the lung cancer field with Alimta, and as this drug is nearing patent expiry, Loxo should provide the firm with opportunities to seize a share of
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
